Sarolaner (Revolution Plus)

Sarolaner is a potent isoxazoline-class ectoparasiticide that has revolutionized flea and tick prevention in cats when combined with selamectin in the product Revolution Plus. This innovative combination medication provides broad-spectrum protection against external and internal parasites, making it one of the most comprehensive antiparasitic treatments available for feline patients. Sarolaner works by targeting the nervous system of parasites, causing rapid paralysis and death of fleas, ticks, and ear mites. The medication has gained widespread acceptance in veterinary medicine due to its efficacy, convenient monthly administration, and excellent safety profile in cats.

The mechanism of action of sarolaner involves selective inhibition of gamma-aminobutyric acid (GABA)-gated chloride channels and glutamate-gated chloride channels in the nervous system of arthropod parasites. This interference with neurotransmission causes uncontrolled neuromuscular activity, leading to paralysis and death of the target parasites. Importantly, sarolaner demonstrates high selectivity for invertebrate receptors over mammalian receptors, which accounts for its favorable safety margin in cats. The drug begins killing fleas within 12 hours of application and maintains efficacy for a full month, breaking the flea life cycle and preventing environmental infestation.

Revolution Plus, which contains sarolaner combined with selamectin, is available as a topical solution applied directly to the skin at the base of the cat's neck. The product comes in various concentrations designed for different weight ranges, ensuring appropriate dosing for cats from 2.8 pounds to over 22 pounds. The topical formulation is absorbed through the skin and distributed systemically, providing protection against parasites that bite and feed on the cat. Monthly application is straightforward, making compliance relatively easy for cat owners to maintain throughout the year or during peak parasite seasons.

The safety profile of sarolaner in cats has been extensively studied, with clinical trials demonstrating good tolerability when used according to label directions. However, as with all medications, veterinary supervision is essential to ensure appropriate use and to monitor for any adverse reactions. Proper dosing based on accurate body weight is crucial for both efficacy and safety. Cat owners should complete the full recommended treatment course and maintain regular monthly applications to achieve optimal parasite control and prevent reinfestation from the environment or exposure to other animals.

The primary indication for sarolaner in cats, as formulated in Revolution Plus, is the prevention and treatment of flea infestations caused by Ctenocephalides felis. Flea infestations are among the most common parasitic conditions affecting cats worldwide, causing significant discomfort, skin irritation, and potentially transmitting other diseases such as Bartonella and tapeworms. Sarolaner kills adult fleas before they can lay eggs, effectively breaking the flea life cycle and preventing the development of environmental infestations that can persist for months in household carpeting, bedding, and furniture. This makes it a first-line choice for both treating active infestations and providing ongoing preventive care.

Beyond flea control, sarolaner provides excellent efficacy against multiple tick species that parasitize cats. The medication kills black-legged ticks (Ixodes scapularis), Gulf Coast ticks (Amblyomma maculatum), and American dog ticks (Dermacentor variabilis), protecting cats from tick-borne diseases that can cause serious illness. While cats are generally less susceptible to some tick-borne diseases than dogs, they can still be affected by conditions such as cytauxzoonosis, which can be fatal. Monthly sarolaner application provides continuous protection for cats that spend time outdoors or in environments where tick exposure is possible.

Sarolaner is also highly effective against ear mites (Otodectes cynotis), which are extremely common parasites in cats, particularly kittens and cats from shelters or multi-cat environments. Ear mites cause intense itching, head shaking, and dark discharge from the ear canals, leading to significant discomfort and potential secondary infections. A single application of Revolution Plus has been shown to eliminate ear mite infestations, although severely affected cats may require additional supportive care for secondary ear infections.

The selamectin component of Revolution Plus adds protection against intestinal parasites including roundworms (Toxocara cati) and hookworms (Ancylostoma tubaeforme), as well as heartworm prevention through activity against Dirofilaria immitis larvae. This broad-spectrum coverage makes the combination product particularly valuable for cats with potential exposure to multiple parasite types. Outdoor cats, cats in multi-pet households, and cats from rescue situations often benefit most from this comprehensive approach to parasite control.

Veterinarians may select sarolaner-containing products over other antiparasitics based on several factors including the specific parasites present in the geographic area, the cat's lifestyle and exposure risk, previous treatment failures with other products, and owner preference for topical versus oral administration. The once-monthly dosing schedule and broad spectrum of activity make Revolution Plus particularly attractive for owners seeking comprehensive parasite prevention in a single convenient application. Cost considerations and the cat's tolerance of topical application also influence product selection decisions.

The dosing protocol for sarolaner in cats follows a weight-based system designed to ensure adequate drug exposure across the feline population while maintaining appropriate safety margins. Revolution Plus is available in three formulations corresponding to different weight ranges: cats weighing 2.8 to 5.5 pounds receive the smallest tube, cats weighing 5.6 to 11 pounds receive the medium tube, and cats weighing 11.1 to 22 pounds receive the largest tube. For cats exceeding 22 pounds, veterinarians may recommend using an appropriate combination of tubes to achieve the correct dose. The veterinarian determines the appropriate product size based on accurate body weight measurement at each visit.

The recommended dosing provides a minimum of 1 mg/kg sarolaner combined with 6 mg/kg selamectin applied topically once monthly. This dosing regimen has been established through extensive clinical trials demonstrating both efficacy against target parasites and safety in the feline population. The loading dose and maintenance dose are identical for this product, simplifying the treatment protocol. There is no need for more frequent application during heavy infestations, as the standard monthly dose provides sufficient drug levels to eliminate existing parasites and prevent new infestations throughout the dosing interval.

Treatment duration varies depending on the clinical situation and goals of therapy. For flea prevention in endemic areas, year-round monthly application is recommended to maintain continuous protection and prevent establishment of environmental flea populations. In areas with seasonal flea activity, treatment may be administered during peak months, though many veterinarians recommend year-round prevention given the ability of fleas to survive indoors during winter. For ear mite treatment, a single application is typically sufficient, though veterinary follow-up is recommended to confirm resolution. Heartworm prevention requires consistent monthly administration throughout the mosquito season at minimum, with year-round protection recommended in many geographic areas.

To administer Revolution Plus, the cat should be restrained gently but securely. Part the fur at the base of the skull, between the shoulder blades, to expose the skin. Apply the entire contents of the tube directly to the skin in one spot. The application site should be dry, and cats should not be bathed for at least two hours after application to ensure complete absorption. Avoid application to broken or irritated skin. The medication spreads across the skin surface and is absorbed systemically over the following hours. It is normal for the application site to appear slightly oily or have matted fur temporarily after application.

If a monthly dose is missed, apply Revolution Plus as soon as the missed dose is remembered, then resume the regular monthly schedule. Do not apply two doses simultaneously to make up for a missed application, as this could increase the risk of adverse effects without providing additional benefit. If multiple doses have been missed, consult with a veterinarian about the appropriate approach to reestablishing protection, particularly if the cat has been exposed to parasites during the gap in coverage. For cats in heartworm-endemic areas, heartworm testing may be recommended before resuming prevention after an extended gap.

Completing the full recommended treatment course and maintaining consistent monthly applications is essential for optimal parasite control. Stopping treatment prematurely or inconsistently can allow parasite populations to rebound, potentially leading to environmental infestation and ongoing exposure. For flea control specifically, treating all pets in the household simultaneously and implementing environmental management strategies enhances overall success. Cat owners should maintain regular veterinary appointments to monitor treatment response and adjust the parasite prevention protocol as the cat's weight, lifestyle, or exposure risks change.

Sarolaner in cats, as formulated in Revolution Plus, demonstrates an excellent safety profile when used according to label directions, with the majority of cats tolerating treatment without adverse effects. Clinical trials supporting FDA approval showed that adverse reactions were generally mild and self-limiting. However, as with any medication, cat owners should be aware of potential side effects and monitor their pets during treatment. Understanding what reactions might occur and when to seek veterinary attention helps ensure prompt intervention if needed.

The most commonly observed side effects in cats treated with Revolution Plus involve mild, localized reactions at the application site. Some cats may experience temporary hair loss, skin irritation, or mild erythema where the product was applied. These reactions typically resolve within a few days without intervention. Occasionally, cats may exhibit transient itchiness or discomfort immediately after application, which usually subsides quickly. Some cats may groom the application site if they can reach it, which can result in mild salivation or hypersalivation due to the taste of the product. Applying the medication high on the neck between the shoulder blades helps minimize this behavior.

Gastrointestinal effects have been reported in some cats following sarolaner administration, though these occur relatively infrequently. Affected cats may experience vomiting, diarrhea, or decreased appetite that is typically mild and resolves without specific treatment. If gastrointestinal signs persist for more than 24 to 48 hours or are accompanied by lethargy or dehydration, veterinary evaluation is warranted to rule out other causes and provide supportive care if needed. Ensuring the cat does not ingest the product by applying it to an inaccessible area helps reduce the likelihood of gastrointestinal upset.

More serious adverse effects, while uncommon, require immediate veterinary attention. Neurological signs including tremors, ataxia (uncoordinated movement), or seizures have been reported rarely with isoxazoline-class drugs in cats. These effects appear to be more likely in cats with pre-existing neurological conditions or those that receive higher than recommended doses. If a cat exhibits any neurological abnormalities following application, the product should not be reapplied, and the cat should be evaluated by a veterinarian promptly. Allergic reactions, though rare, can manifest as facial swelling, hives, difficulty breathing, or collapse and constitute veterinary emergencies.

Rare side effects and long-term concerns with sarolaner use in cats remain under ongoing surveillance through post-market reporting systems. Some cats may exhibit lethargy or behavioral changes following application, which typically resolve within a day or two. Individual cats may show sensitivity not observed during clinical trials, emphasizing the importance of monitoring after each application, particularly when starting a new medication. Cat owners should report any unexpected reactions to their veterinarian, who can determine whether continued use is appropriate and report significant adverse events to the manufacturer and FDA. When in doubt about whether symptoms are related to the medication, veterinary consultation is always appropriate.

Sarolaner should not be administered to cats with known hypersensitivity or allergy to sarolaner, selamectin, or any other component of the Revolution Plus formulation. While true allergic reactions to isoxazoline-class drugs are uncommon in cats, any cat that has previously experienced an adverse reaction to sarolaner or related compounds should not receive this medication again. Cross-reactivity between different isoxazoline drugs (such as sarolaner, fluralaner, and lotilaner) has not been extensively studied, so caution is warranted when considering alternative isoxazoline products for cats that reacted to sarolaner. Cat owners should inform their veterinarian of any previous adverse reactions to antiparasitic medications.

Cats with significant hepatic dysfunction require careful consideration before sarolaner administration. The liver plays a central role in drug metabolism, and impaired hepatic function can alter drug clearance, potentially leading to elevated drug levels and increased risk of toxicity. While specific studies evaluating sarolaner in cats with liver disease are limited, veterinarians typically exercise caution when prescribing systemically absorbed medications to cats with known hepatic compromise. Similarly, cats with severe renal impairment warrant careful evaluation, though the primary elimination pathway for sarolaner does not appear to be renal excretion. Baseline organ function testing may be recommended for cats with suspected metabolic compromise.

Revolution Plus should not be used in kittens under 8 weeks of age or in cats weighing less than 2.8 pounds, as safety and efficacy have not been established in these populations. Young kittens have immature hepatic metabolism and may be more susceptible to adverse effects from systemically absorbed medications. Pregnant or lactating cats represent another population where caution is warranted, as the safety of sarolaner during pregnancy and nursing has not been fully evaluated in cats. Veterinarians may recommend alternative antiparasitic options for breeding queens or defer treatment until after weaning when possible. The reproductive safety of sarolaner in male breeding cats has not been evaluated.

Cats with pre-existing neurological conditions, including those with a history of seizures, should be carefully evaluated before receiving isoxazoline-class drugs including sarolaner. While the incidence of neurological adverse effects is low in healthy cats, those with underlying seizure disorders or other neurological disease may be at increased risk. The decision to use sarolaner in such cats should be made on a case-by-case basis, weighing the benefits of parasite control against potential risks. Cat owners should provide their veterinarian with a complete medical history, including any previous seizures, tremors, or neurological episodes, as well as a list of all current medications and supplements. This comprehensive information allows the veterinarian to make the most appropriate treatment recommendations for each individual patient.

Before initiating sarolaner therapy, cat owners should inform their veterinarian of all medications, supplements, and treatments their cat currently receives. Drug interactions can affect the efficacy of antiparasitic treatment or increase the risk of adverse effects from either medication. While sarolaner has not demonstrated extensive interactions with other commonly used feline medications, the potential for interactions exists with any drug that shares metabolic pathways or has additive effects on body systems. Comprehensive medication disclosure enables the veterinarian to assess potential interactions and adjust the treatment plan accordingly.

Isoxazoline-class drugs including sarolaner are metabolized primarily by the cytochrome P450 enzyme system in the liver. Other medications that induce or inhibit these enzymes could theoretically alter sarolaner blood levels, though clinically significant interactions have not been widely reported. Drugs that strongly induce hepatic metabolism, such as phenobarbital used for seizure control, might reduce sarolaner concentrations and potentially compromise antiparasitic efficacy. Conversely, drugs that inhibit hepatic metabolism could increase sarolaner levels and theoretically increase risk of adverse effects. Cats receiving long-term medications metabolized by the liver should be monitored appropriately when starting sarolaner therapy.

Concerns have been raised about concurrent use of isoxazoline antiparasitics with other drugs that affect neurological function. While direct interactions have not been established, cats receiving medications that lower seizure threshold or affect GABA neurotransmission may warrant additional monitoring. This includes cats on certain anesthetic protocols, some psychiatric medications, or those receiving other antiparasitic drugs with neurological effects. The selamectin component of Revolution Plus is a macrocyclic lactone, and while drug interactions with selamectin in cats are minimal, concurrent use with other macrocyclic lactones (such as ivermectin or moxidectin) could theoretically result in additive effects and should be managed carefully.

Dietary factors and supplements generally do not significantly impact sarolaner efficacy since the drug is applied topically and absorbed through the skin rather than ingested. However, topical products such as medicated shampoos, other spot-on treatments, or skin barrier products could potentially affect absorption if applied to the same area. Revolution Plus should not be applied concurrently with other topical parasiticides, and appropriate intervals should be maintained between bathing and product application. Cat owners using any topical treatments should discuss timing and application sites with their veterinarian. Signs of potential drug interactions to monitor include increased lethargy, gastrointestinal upset, neurological changes, or lack of expected efficacy against parasites. Any concerns about possible interactions should be discussed with the prescribing veterinarian promptly.

Standard precautions for sarolaner use in cats emphasize the importance of proper product selection, accurate dosing, and appropriate monitoring during treatment. The product should only be used under veterinary supervision to ensure it is appropriate for the individual cat's health status and parasite control needs. Accurate body weight determination at each application is essential, as underdosing may result in treatment failure while overdosing increases adverse effect risk. Cat owners should not estimate weight or use outdated measurements when selecting product size. Following label directions precisely, including application technique and timing, maximizes both safety and efficacy.

Certain cat breeds may exhibit different sensitivities to medications, though breed-specific reactions to sarolaner have not been extensively documented. Veterinarians and cat owners should be aware that individual variation exists within any population, and cats of any breed may show unexpected responses to new medications. Cats with the MDR1 gene mutation, while less common than in dogs, may have altered drug transport across the blood-brain barrier, potentially affecting response to certain medications. The clinical significance of this mutation for sarolaner in cats is not well established, but awareness of individual variation supports careful monitoring.

Environmental and handling precautions are important when using topical parasiticide products. Cat owners should avoid direct contact with the product during application by wearing gloves or washing hands thoroughly afterward. The product should not be applied to broken, irritated, or infected skin. In multi-pet households, treated cats should be separated from other animals and children until the application site is dry to prevent grooming ingestion or transfer. The product is harmful to aquatic organisms, so cats should not be allowed to swim or enter natural water bodies immediately following application, and used tubes should be disposed of properly rather than flushed.

Monitoring during treatment involves observing for both efficacy and adverse effects. Cat owners should watch for signs of continued parasitism, such as visible fleas, flea dirt, excessive scratching, or symptoms of ear mites, which could indicate treatment failure or reinfestation. Adverse effect monitoring includes observing for application site reactions, behavioral changes, gastrointestinal upset, or any neurological signs. A baseline assessment of the cat's normal behavior, appetite, and activity level helps owners recognize changes that might indicate a problem. Any concerns should be reported to the veterinarian promptly.

Special consideration is needed for certain cat populations. Geriatric cats may have age-related organ function decline affecting drug metabolism and elimination, warranting careful dosing and monitoring. Kittens younger than 8 weeks should not receive this product, and young cats approaching the minimum age should be treated with appropriate attention to accurate weight-based dosing. Immunocompromised cats, whether due to disease or immunosuppressive treatment, may have altered responses to parasitic infections and potentially different safety profiles with antiparasitic medications. Cats with chronic conditions requiring multiple medications need comprehensive evaluation to ensure sarolaner fits safely within their overall treatment plan.

Revolution Plus containing sarolaner should be stored at controlled room temperature, between 68°F and 77°F (20°C to 25°C), though brief excursions to temperatures between 59°F and 86°F (15°C to 30°C) are generally acceptable during transport or temporary storage variations. The product should be protected from light and stored in its original packaging until use. Avoid storing the medication in areas subject to extreme temperature fluctuations, such as vehicles, garages, or near heating vents or windows with direct sunlight exposure. Excessive heat can degrade the active ingredients, potentially reducing efficacy, while freezing should also be avoided. The storage location should maintain consistent conditions to preserve product integrity throughout its shelf life.

The topical solution tubes are designed for single-dose use and should remain sealed until immediately before application. Once a tube is opened, the entire contents should be applied to the cat, and any remaining product should not be stored for later use. Before application, visually inspect the product for any changes in color, consistency, or clarity that might indicate degradation. The solution should appear clear to slightly yellow. Do not use product that appears cloudy, discolored, or contains particulate matter. Always check the expiration date printed on the packaging before use, as expired product may have reduced efficacy against parasites and should be discarded appropriately.

Safe handling and disposal practices protect both household members and the environment. Keep Revolution Plus out of reach of children and pets in a secure storage location. When applying the product, work in a well-ventilated area and avoid contact with eyes, skin, or clothing. If accidental exposure occurs, wash the affected area with soap and water. In case of eye contact, rinse thoroughly with water and seek medical attention if irritation persists. Used applicator tubes retain residual product and should be disposed of in household trash rather than recycling, ensuring they cannot be accessed by children or animals. Do not dispose of unused product in drains or water systems due to potential aquatic toxicity. Many veterinary clinics and pharmacies participate in medication take-back programs that provide safe disposal options for unused or expired parasiticides.

The vast majority of cat breeds tolerate sarolaner-containing products well when used according to label directions, as the medication has been evaluated across diverse feline populations during clinical development. Breed-specific adverse reactions to sarolaner have not been prominently identified in veterinary literature, suggesting that the drug has broad applicability across the feline population. However, veterinarians and cat owners should recognize that individual variation exists within every breed, and any cat may exhibit unexpected sensitivity to new medications regardless of breed background.

While breed-specific sensitivities to sarolaner are not well documented, certain considerations apply to particular breed types. Hairless breeds such as the Sphynx or Peterbald have different skin characteristics that could potentially affect topical product absorption, though clinical significance has not been established. These cats may require modified application technique, and owners should discuss appropriate use with their veterinarian. Breeds with very dense or long coats, such as Persians or Maine Coons, may require careful fur parting to ensure the product reaches the skin surface for proper absorption. The medication must contact the skin directly to be absorbed effectively.

Size variation among cat breeds creates dosing considerations that transcend breed-specific sensitivity. Large breeds such as Maine Coons, Ragdolls, and Norwegian Forest Cats may approach or exceed the upper weight limit of standard product sizes, requiring careful product selection and potentially combination of tubes to achieve appropriate dosing. Conversely, small breeds and naturally petite cats require precise dosing to avoid overdose while ensuring adequate parasite control. Oriental breeds such as Siamese, which tend toward lighter body weight, should be weighed accurately before each application. Accurate scaling at veterinary visits ensures appropriate product selection regardless of breed.

Age-related considerations often overlap with breed factors in determining appropriate antiparasitic use. Kittens of any breed under 8 weeks of age should not receive Revolution Plus, as safety has not been established in this population. Young cats should be weighed frequently as they grow to ensure continued appropriate dosing. Senior cats of any breed may have age-related organ function changes that affect drug metabolism, though specific breed predispositions to geriatric sensitivities with sarolaner have not been identified. Regular veterinary assessment helps identify any age or breed-related factors that should influence treatment decisions, and maintaining open communication about the cat's response to medication supports optimal care.

Within the isoxazoline class of antiparasitics, several alternatives to sarolaner are available for cats. Fluralaner, marketed as Bravecto for cats, is another isoxazoline that provides extended-duration flea and tick control, with some formulations offering protection for up to 12 weeks from a single topical application. Lotilaner, available in Credelio Cat, is an oral isoxazoline option for cats that prefer or tolerate oral administration better than topical products. Each isoxazoline has slightly different duration of action and spectrum of activity, allowing veterinarians to select products based on individual patient needs, owner preferences, and regional parasite pressures. Cats that experience adverse reactions to one isoxazoline may or may not tolerate alternatives in the same class.

Different antiparasitic drug classes offer options when isoxazolines are not appropriate. Selamectin alone (Revolution) provides flea prevention, heartworm protection, and treatment for ear mites and intestinal parasites without the isoxazoline component, though it lacks the tick efficacy that sarolaner provides. Fipronil-based products (Frontline) offer topical flea and tick control through a different mechanism targeting insect chloride channels. Imidacloprid combinations provide flea control and may include additional active ingredients for broader parasite coverage. Spinosad (Comfortis) offers oral flea control as an alternative to topical application. The choice among these classes depends on the specific parasites targeted, the cat's health status, and any history of adverse reactions.

Complementary approaches to parasite control can enhance the effectiveness of pharmaceutical treatment. Environmental management including regular vacuuming, washing bedding in hot water, and treating the home environment helps eliminate flea life stages not on the cat. Maintaining treated cats indoors or limiting outdoor access reduces exposure to ticks and other parasites. Some owners utilize flea combs for mechanical removal and monitoring. Probiotics and immune-supporting supplements may help maintain overall health during treatment, though they do not replace pharmaceutical parasite control. Veterinary guidance is essential when considering any changes to an established parasite prevention protocol, as substituting products or altering treatment schedules without professional input can lead to gaps in protection or inappropriate drug combinations.